A NOVEL NON-INVASIVE DNA METHYLATION TEST FOR MELANOMAbroad
MitraTest · Horizon Europe grant · 2025-11-01–2027-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2025-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2025-ACCELERATOR-02-OPEN-01. CORDIS record →
Objective
Early cancer detection is a key to improve survival rates. For melanoma the survival falls from >98% at Stage 1 to 22% at Stage 4.Currently, skin biopsy is the only method of melanoma detection. It is an expensive and invasive procedure. Our patented technology, is a combination of a unique non-invasive tape strip skin sample collection technique and proprietary DNA methylation panel specific for melanoma. This will allow quick and inexpensive testing for melanoma at GP level and as an at-home test kit.Our proof of concept study with Guy’s Hospital (UK) showed over 95% specificity and 85% sensitivity in detecting melanoma compared to standard biopsy procedures.Mitra Bio is a female-led team of 6 scientists and business developers with experience in building diagnostics platforms. We aim to improve melanoma detection and reduce melanoma health and economic burden, which currently results in 15K deaths/year in the EU.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| MITRA BIO LIMITED | UK | coordinator | €2,499,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.